Insilico Medicine, a clinical-stage artificial intelligence (AI)-driven drug discovery startup, has closed the second tranche of its Series D round led by new investor Prosperity7 Ventures, the diversified growth fund of oil giant Saudi Aramco’s Aramco Ventures.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
